The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid shifting expectations across growth sectors, recent corporate updates highlight a divergence between digital advertising and medical technology outlooks. Nexxen raised its 2026 programmatic revenue growth outlook to 13% during its Investor Day, citing strong AI capabilities. Conversely, Morgan Stanley downgraded ResMed to Equalweight, citing concerns over margin expansion and the competitive impact of Philips' re-entry into the U.S. market.
Sign in to access this content
Sign InThe downgrade of ResMed comes as investors scrutinize supply chain stability in the healthcare sector, with Morgan Stanley analysts noting that flat gross margins could cap the stock's upside. Compared to its peers, ResMed faces renewed pressure as Philips resumes operations in the U.S., creating pricing and competitive headwinds per market data. Recent earnings reports from medical device peers also indicate a trend of rising acquisition costs, further justifying the cautious stance on margin growth in the current environment.
Regarding price action, RMD closed at $192.74 (close June 15, 2026), trading within a daily range of $191.65 to $197.41 according to market data. Traders are looking ahead to key U.S. economic catalysts, including the Initial Jobless Claims report scheduled for June 11, 2026. Investors will also closely monitor further communications from Philips to assess the pace of its market share recovery and its subsequent impact on ResMed's current support levels.